Jia Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jia Zhu has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Junting Huang
Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China
16 shared publications Juan Wang
15 shared publications- Zijun Zhen
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
11 shared publications - Yizhuo Zhang
Sun Yat-sen University Cancer Center
10 shared publications Suying Lu
9 shared publications- Feifei Sun
Sun Yat-sen University Cancer Center
8 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Elsevier in SSRN Electronic Journal
Apatinib Combined with Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma Followed by Apatinib Maintenance Therapy (AIT-NB-01): A Multicentre, Single-Arm, Phase 1/2 Trial
Background: Relapsed or refractory neuroblastoma remains a major therapeutic challenge. Apatinib is an oral multi-target tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor 2 (VEGFR-2). We evaluated the safety, efficacy, and pharmacokinetics of apatinib combined with irinotecan and temozolomide in patients with relapsed or refractory neuroblastoma.Methods: AIT-NB-01 is a multicentre, single-arm, phase 1/2 trial conducted across five centres in China. Patients aged ≥2 years with relapsed or refractory high-risk neuroblastoma were eligible for this study. In phase 1, apatinib (150, 300, or 450 mg/m2) combined with irinotecan (50 mg/m2 intravenously, days 1–5) and temozolomide (150 mg/m2 intravenously, days 1–5) was evaluated using a 3+3 design. In phase 2, patients received apatinib at the recommended phase 2 dose (RP2D) for up to eight cycles, followed by apatinib maintenance until disease progression or unacceptable toxicity. The primary endpoint were the maximum tolerated dose, RP2D and dose-limiting toxicity in phase 1, and best objective response rate (ORR) at the RP2D in phase 2. This completed trial has been registered with ClinicalTrials.gov (NCT05027386).Findings: Between September 2021 and September 2024, 111 patients were enrolled (23 in phase 1; 88 in phase 2). The RP2D of apatinib was 300 mg/m2. Among 96 patients eligible for efficacy at the RP2D, 53 achieved an objective response (ORR: 55%, 95% confidence interval [CI]: 45–65). At a median follow-up of 24·9 months (interquartile range: 16·5–32·9), the median progression–free survival (PFS) was 11·7 (95% CI 10·4–16·6) months. Patients who received apatinib maintenance therapy had significantly longer PFS (median: 16·6 vs. 10·6 months; hazard ratio: 0·61, 95% CI: 0·37–1·00; p=0·0478). Grade 3–4 adverse events occurred in 68 (61%) patients, of which the most common were leukopenia (27%), neutropenia (25%), and thrombocytopenia (20%). Two serious treatment-related adverse events and no treatment-related deaths were reported.Interpretation: Apatinib combined with irinotecan and temozolomide demonstrated promising efficacy with a manageable safety profile in patients with relapsed or refractory neuroblastoma. Oral apatinib maintenance therapy was associated with improved PFS. Further evaluation in randomised controlled trials is warranted.
- 10 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessApatinib Combined with Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma Followed by Apatinib Maintenance Therapy (AIT-NB-01): A Multicentre, Single-Arm, Phase 1/2 Trial
Background: Relapsed or refractory neuroblastoma remains a major therapeutic challenge. Apatinib is an oral multi-target tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor 2 (VEGFR-2). We evaluated the safety, efficacy, and pharmacokinetics of apatinib combined with irinotecan and temozolomide in patients with relapsed or refractory neuroblastoma.Methods: AIT-NB-01 is a multicentre, single-arm, phase 1/2 trial conducted across five centres in China. Patients aged ≥2 years with relapsed or refractory high-risk neuroblastoma were eligible for this study. In phase 1, apatinib (150, 300, or 450 mg/m2) combined with irinotecan (50 mg/m2 intravenously, days 1–5) and temozolomide (150 mg/m2 intravenously, days 1–5) was evaluated using a 3+3 design. In phase 2, patients received apatinib at the recommended phase 2 dose (RP2D) for up to eight cycles, followed by apatinib maintenance until disease progression or unacceptable toxicity. The primary endpoint were the maximum tolerated dose, RP2D and dose-limiting toxicity in phase 1, and best objective response rate (ORR) at the RP2D in phase 2. This completed trial has been registered with ClinicalTrials.gov (NCT05027386).Findings: Between September 2021 and September 2024, 111 patients were enrolled (23 in phase 1; 88 in phase 2). The RP2D of apatinib was 300 mg/m2. Among 96 patients eligible for efficacy at the RP2D, 53 achieved an objective response (ORR: 55%, 95% confidence interval [CI]: 45–65). At a median follow-up of 24·9 months (interquartile range: 16·5–32·9), the median progression–free survival (PFS) was 11·7 (95% CI 10·4–16·6) months. Patients who received apatinib maintenance therapy had significantly longer PFS (median: 16·6 vs. 10·6 months; hazard ratio: 0·61, 95% CI: 0·37–1·00; p=0·0478). Grade 3–4 adverse events occurred in 68 (61%) patients, of which the most common were leukopenia (27%), neutropenia (25%), and thrombocytopenia (20%). Two serious treatment-related adverse events and no treatment-related deaths were reported.Interpretation: Apatinib combined with irinotecan and temozolomide demonstrated promising efficacy with a manageable safety profile in patients with relapsed or refractory neuroblastoma. Oral apatinib maintenance therapy was associated with improved PFS. Further evaluation in randomised controlled trials is warranted.
- Open Access
- 21 May 2026
- Published by Elsevier in SSRN Electronic Journal
Long-Term Survival, Late Complications, Quality of Life, and Fertility in Chinese Pediatric and Young Adult Hodgkin Lymphoma Survivors
Background: This study aimed to explore long-term survival, late complications, and quality of life (QoL) in Chinese childhood, adolescent, and young adult (CAYA) Hodgkin lymphoma (HL) survivors to optimize individualized long-term follow-up strategies.Methods: A single-center retrospective analysis enrolled CAYA-HL patients diagnosed at the age of ≤25 years and surviving ≥2 years during 1993–2022. Survival outcomes, late complications, QoL, and fertility status were systematically assessed. Kaplan–Meier, Fine–Gray, and Cox regression models were adopted for statistical analysis.Findings: With a median follow-up of 8.9 years in 602 patients, the 10- and 20-year overall survival (OS) rates were 94.7% and 91.5%, respectively. Of these, 370 completed the QoL and fertility surveys. High-risk disease and slow initial treatment response were independent prognostic predictors of poor OS. Primary relapse or progression (80.7%) and SMNs (6.5%) were the main causes of late death. Relapse occurred in 92 patients, and 5 developed SMNs (10-year cumulative incidence 1.2%, 15-year cumulative incidence 2.5%). Chest radiotherapy was an independent risk factor for SMNs. Common late complications were thyroid disease (6.8%), pulmonary nodules (4.9%), and cardiovascular events (3.5%). An older diagnosis age (>17 years) and relapsed/ refractory (R/R) disease both significantly impaired QoL. The cohort showed an exceptionally high post-marital fertility rate of 82.0%.Interpretation: Chinese CAYA-HL survivors have favorable long-term survival but face risks of late complications and reduced QoL. Targeted surveillance, disease management, psychosocial intervention and fertility counseling are warranted to improve long-term health management.
- 21 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLong-Term Survival, Late Complications, Quality of Life, and Fertility in Chinese Pediatric and Young Adult Hodgkin Lymphoma Survivors
Background: This study aimed to explore long-term survival, late complications, and quality of life (QoL) in Chinese childhood, adolescent, and young adult (CAYA) Hodgkin lymphoma (HL) survivors to optimize individualized long-term follow-up strategies.Methods: A single-center retrospective analysis enrolled CAYA-HL patients diagnosed at the age of ≤25 years and surviving ≥2 years during 1993–2022. Survival outcomes, late complications, QoL, and fertility status were systematically assessed. Kaplan–Meier, Fine–Gray, and Cox regression models were adopted for statistical analysis.Findings: With a median follow-up of 8.9 years in 602 patients, the 10- and 20-year overall survival (OS) rates were 94.7% and 91.5%, respectively. Of these, 370 completed the QoL and fertility surveys. High-risk disease and slow initial treatment response were independent prognostic predictors of poor OS. Primary relapse or progression (80.7%) and SMNs (6.5%) were the main causes of late death. Relapse occurred in 92 patients, and 5 developed SMNs (10-year cumulative incidence 1.2%, 15-year cumulative incidence 2.5%). Chest radiotherapy was an independent risk factor for SMNs. Common late complications were thyroid disease (6.8%), pulmonary nodules (4.9%), and cardiovascular events (3.5%). An older diagnosis age (>17 years) and relapsed/ refractory (R/R) disease both significantly impaired QoL. The cohort showed an exceptionally high post-marital fertility rate of 82.0%.Interpretation: Chinese CAYA-HL survivors have favorable long-term survival but face risks of late complications and reduced QoL. Targeted surveillance, disease management, psychosocial intervention and fertility counseling are warranted to improve long-term health management.
- Open Access
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (1) , e2500428
Precision Medicine Program in Chinese Pediatric Patients With Sarcoma
PURPOSE: Molecular profiles of sarcomas in Chinese children remain unknown. The Chinese Pediatric Precision Oncology Group (CPPOG) is a prospective precision medicine program aimed at defining tumor molecular profiles in pediatric oncology patients across China, which aids diagnosis and treatment decisions. Herein, we report, to our knowledge, the first data from the CPPOG trial. METHODS: Panel sequencing (830-gene DNA panel and 395-gene RNA panel) was performed on 214 tumors from 210 patients with sarcoma from 11 centers, between April 2021 and January 2022 in China. This study was prospectively analyzed to characterize subtype-specific somatic alterations and pathways. Molecular features among subgroups concerning response to treatment and pathologic characteristics were also identified. RESULTS: Genomic profiling revealed molecular aberrations in the patients: 88.3% harbored at least one somatic or germline alteration; 51.4% carried gene fusions (including 37 novel fusion variants); 46.3% possessed actionable therapeutic targets; 9.5% exhibited germline variants; and 14.3% had modified diagnoses based on molecular findings. In this study, the most common genetic alterations were TP53 mutation and EWSR1-FLI1 fusion. The most common activated pathways were TP53, PI3K, and RTK-RAS in pediatric sarcomas. Anaplastic embryonal rhabdomyosarcomas had special molecular characteristics, with high TP53 , MYCN , and MYCL gene alteration frequencies. The mutation frequencies of TP53 and NRAS were notably higher in patients who had undergone disease progression, relapse, or metastasis. Moreover, MYC , MYCN , and MDM2 alterations were more frequent in tumors with mitotic figures >50/3 mm 2 . CONCLUSION: Our study reveals the preliminary molecular landscape of Chinese pediatric sarcomas, indicating that molecular changes may represent different therapeutic responses and pathologic characteristics may correlate with molecular characteristics, suggesting the need for panel sequencing for pediatric sarcoma.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (1) , e2500428
Open AccessPrecision Medicine Program in Chinese Pediatric Patients With Sarcoma
PURPOSE: Molecular profiles of sarcomas in Chinese children remain unknown. The Chinese Pediatric Precision Oncology Group (CPPOG) is a prospective precision medicine program aimed at defining tumor molecular profiles in pediatric oncology patients across China, which aids diagnosis and treatment decisions. Herein, we report, to our knowledge, the first data from the CPPOG trial. METHODS: Panel sequencing (830-gene DNA panel and 395-gene RNA panel) was performed on 214 tumors from 210 patients with sarcoma from 11 centers, between April 2021 and January 2022 in China. This study was prospectively analyzed to characterize subtype-specific somatic alterations and pathways. Molecular features among subgroups concerning response to treatment and pathologic characteristics were also identified. RESULTS: Genomic profiling revealed molecular aberrations in the patients: 88.3% harbored at least one somatic or germline alteration; 51.4% carried gene fusions (including 37 novel fusion variants); 46.3% possessed actionable therapeutic targets; 9.5% exhibited germline variants; and 14.3% had modified diagnoses based on molecular findings. In this study, the most common genetic alterations were TP53 mutation and EWSR1-FLI1 fusion. The most common activated pathways were TP53, PI3K, and RTK-RAS in pediatric sarcomas. Anaplastic embryonal rhabdomyosarcomas had special molecular characteristics, with high TP53 , MYCN , and MYCL gene alteration frequencies. The mutation frequencies of TP53 and NRAS were notably higher in patients who had undergone disease progression, relapse, or metastasis. Moreover, MYC , MYCN , and MDM2 alterations were more frequent in tumors with mitotic figures >50/3 mm 2 . CONCLUSION: Our study reveals the preliminary molecular landscape of Chinese pediatric sarcomas, indicating that molecular changes may represent different therapeutic responses and pathologic characteristics may correlate with molecular characteristics, suggesting the need for panel sequencing for pediatric sarcoma.
- 20 February 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31613
Prognostic Value of Peripheral Blood Lymphocyte Subsets in Children and Adolescents With High‐Grade Mature B‐Cell Non‐Hodgkin Lymphoma: A Real‐World Outcomes Study
Background: Little progress has been made in determining prognostic factors for patients with high‐grade mature B‐cell non‐Hodgkin lymphoma (HG B‐NHL). Based on the important role of lymphocytes in cancer progression, this study aimed to explore the effect of peripheral blood lymphocytes on the prognosis of pediatric HG B‐NHL. Methods: Patients aged less than 18 years with newly diagnosed HG B‐NHL were enrolled. Peripheral blood lymphocyte subset levels were detected at diagnosis, and their optimal cutoff values were determined according to event‐free survival (EFS). Results: In total, 206 patients were enrolled. The 5‐year EFS and overall survival (OS) rates of the whole group were 92.1% ± 1.9% and 96.6% ± 1.3%, respectively. The 5‐year EFS rate was worse in patients with a low relative CD4 + T‐cell count (87.2% vs. 97.0%, p = 0.008), high relative CD8 + T‐cell count (79.1% vs. 93.4%, p = 0.03), low CD4/CD8 ratio (80.5% vs. 94.2%, p = 0.01), and low B‐cell count (80.0% vs. 93.4%, p = 0.02) at diagnosis than their counterparts. Cox multivariate analysis identified low relative CD4 + T‐cell (HR = 4.91) and B‐cell (HR = 3.87) counts at diagnosis as independent adverse prognostic factors. Patients with simultaneously low levels of CD4 + T and B cells had the worst outcomes in the entire cohort, with a 5‐year EFS rate of 60.0%. Conclusion: Low relative CD4 + T‐cell and B‐cell counts at diagnosis are associated with poor prognosis in children and adolescents with HG B‐NHL in the real world.
- 20 February 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31613
Prognostic Value of Peripheral Blood Lymphocyte Subsets in Children and Adolescents With High‐Grade Mature B‐Cell Non‐Hodgkin Lymphoma: A Real‐World Outcomes Study
Background: Little progress has been made in determining prognostic factors for patients with high‐grade mature B‐cell non‐Hodgkin lymphoma (HG B‐NHL). Based on the important role of lymphocytes in cancer progression, this study aimed to explore the effect of peripheral blood lymphocytes on the prognosis of pediatric HG B‐NHL. Methods: Patients aged less than 18 years with newly diagnosed HG B‐NHL were enrolled. Peripheral blood lymphocyte subset levels were detected at diagnosis, and their optimal cutoff values were determined according to event‐free survival (EFS). Results: In total, 206 patients were enrolled. The 5‐year EFS and overall survival (OS) rates of the whole group were 92.1% ± 1.9% and 96.6% ± 1.3%, respectively. The 5‐year EFS rate was worse in patients with a low relative CD4 + T‐cell count (87.2% vs. 97.0%, p = 0.008), high relative CD8 + T‐cell count (79.1% vs. 93.4%, p = 0.03), low CD4/CD8 ratio (80.5% vs. 94.2%, p = 0.01), and low B‐cell count (80.0% vs. 93.4%, p = 0.02) at diagnosis than their counterparts. Cox multivariate analysis identified low relative CD4 + T‐cell (HR = 4.91) and B‐cell (HR = 3.87) counts at diagnosis as independent adverse prognostic factors. Patients with simultaneously low levels of CD4 + T and B cells had the worst outcomes in the entire cohort, with a 5‐year EFS rate of 60.0%. Conclusion: Low relative CD4 + T‐cell and B‐cell counts at diagnosis are associated with poor prognosis in children and adolescents with HG B‐NHL in the real world.
- Open Access
- 24 December 2024
- Published by Wiley
Management and Experiences in Diagnosing and Treating Acute Heart Failure in Children with Solid Tumors
Background: To understand the characteristics and outcomes of acute heart failure (AHF) in children with solid tumors during the treatment process, share treatment experiences, and provide management strategies for monitoring, treatment, and prevention. Methods: Five representative cases of children with solid tumors were selected to summarize the clinical features and treatment effects during the occurrence of AHF. The possible triggers and time points for the onset of AHF were analyzed, along with treatment responses and influencing factors. Results: All five cases of children with solid tumors exhibited symptoms of AHF after chemotherapy, with heart functions staging from class II to class IV. Most cases occurred during the bone marrow suppression period with a noticeable increase in heart rate. All children received oral anti-heart failure treatment and nutritional myocardial therapy. Two children with heart function class II returned to normal after oral medication; three children with heart function class IV received intravenous vasoactive agents followed by regular reinforcement in the later stage. The heart function improved in all three cases (heart function class IV), with one case returning to normal, one case with slow recovery in noncompaction cardiomyopathy gradually approaching normalcy, and one case with only mild improvement in heart function despite concurrent renal dysfunction. Conclusions: Children with solid tumors are susceptible to AHF during the bone marrow suppression period, and an increased heart rate serves as an early warning signal. Active anti-heart failure treatment is effective. Renal dysfunction emerging as a significant factor influencing poor recovery of heart function.
- 24 December 2024
- Published by Wiley
Open AccessManagement and Experiences in Diagnosing and Treating Acute Heart Failure in Children with Solid Tumors
Background: To understand the characteristics and outcomes of acute heart failure (AHF) in children with solid tumors during the treatment process, share treatment experiences, and provide management strategies for monitoring, treatment, and prevention. Methods: Five representative cases of children with solid tumors were selected to summarize the clinical features and treatment effects during the occurrence of AHF. The possible triggers and time points for the onset of AHF were analyzed, along with treatment responses and influencing factors. Results: All five cases of children with solid tumors exhibited symptoms of AHF after chemotherapy, with heart functions staging from class II to class IV. Most cases occurred during the bone marrow suppression period with a noticeable increase in heart rate. All children received oral anti-heart failure treatment and nutritional myocardial therapy. Two children with heart function class II returned to normal after oral medication; three children with heart function class IV received intravenous vasoactive agents followed by regular reinforcement in the later stage. The heart function improved in all three cases (heart function class IV), with one case returning to normal, one case with slow recovery in noncompaction cardiomyopathy gradually approaching normalcy, and one case with only mild improvement in heart function despite concurrent renal dysfunction. Conclusions: Children with solid tumors are susceptible to AHF during the bone marrow suppression period, and an increased heart rate serves as an early warning signal. Active anti-heart failure treatment is effective. Renal dysfunction emerging as a significant factor influencing poor recovery of heart function.
- Open Access
- 27 April 2024
- Published by Wiley
Mechanism of drug resistance to first-line chemotherapeutics mediated by TXNDC17 in neuroblastomas
The prognosis of high-risk neuroblastomas (NB) that are resistant to first-line induction chemotherapy is relatively poor. This study explored the mechanism of resistance to first-line chemotherapeutics mediated by TXNDC17 and its potential solutions in NB. The genetic and clinical data of patients with NB were obtained from the Therapeutically Applicable Research to Generate Effective Treatments dataset. TXNDC17 and BECN1 expressions in NB cells were up- and downregulated by transfection with plasmids and shRNA, respectively. Autophagy-related proteins were detected by western blot. Cell viability was determined using cell proliferation and toxicity experiments. Apoptotic cells were detected using flow cytometry. Overall, 1076 pediatric and adolescent patients with NB were enrolled in this study. The 10-year overall survival (OS) rates and event-free survival (EFS) rates for the patients with mutation of BECN1 were 37.4% ± 9.1% and 34.5% ± 8.8%, respectively. For patients with mutation of TXNDC17, the 10-year OS and EFS were 41.4% ± 5.9% and 24.3% ± 5.1%, respectively, which were significantly lower than those in the unaltered group. The overexpression of BECN1 and TXNDC17 reduced NB sensitivity to cisplatin (DDP), etoposide (VP16), and cyclophosphamide (CTX). Autophagy mediated by BECN1 was regulated by TXNDC17, and this process was involved in the resistance to DDP, VP16, and CTX in NB. Suberoylanilide hydroxamic acid (SAHA) can enhance the sensitivity of NB cells to chemotherapeutics by inhibiting TXNDC17, ultimately decreasing autophagy-mediated chemoresistance. Acquired resistance to first-line chemotherapeutics was associated with autophagy mediated by BECN1 and regulated by TXNDC17, which can be reversed by SAHA.
- 27 April 2024
- Published by Wiley
Open AccessMechanism of drug resistance to first-line chemotherapeutics mediated by TXNDC17 in neuroblastomas
The prognosis of high-risk neuroblastomas (NB) that are resistant to first-line induction chemotherapy is relatively poor. This study explored the mechanism of resistance to first-line chemotherapeutics mediated by TXNDC17 and its potential solutions in NB. The genetic and clinical data of patients with NB were obtained from the Therapeutically Applicable Research to Generate Effective Treatments dataset. TXNDC17 and BECN1 expressions in NB cells were up- and downregulated by transfection with plasmids and shRNA, respectively. Autophagy-related proteins were detected by western blot. Cell viability was determined using cell proliferation and toxicity experiments. Apoptotic cells were detected using flow cytometry. Overall, 1076 pediatric and adolescent patients with NB were enrolled in this study. The 10-year overall survival (OS) rates and event-free survival (EFS) rates for the patients with mutation of BECN1 were 37.4% ± 9.1% and 34.5% ± 8.8%, respectively. For patients with mutation of TXNDC17, the 10-year OS and EFS were 41.4% ± 5.9% and 24.3% ± 5.1%, respectively, which were significantly lower than those in the unaltered group. The overexpression of BECN1 and TXNDC17 reduced NB sensitivity to cisplatin (DDP), etoposide (VP16), and cyclophosphamide (CTX). Autophagy mediated by BECN1 was regulated by TXNDC17, and this process was involved in the resistance to DDP, VP16, and CTX in NB. Suberoylanilide hydroxamic acid (SAHA) can enhance the sensitivity of NB cells to chemotherapeutics by inhibiting TXNDC17, ultimately decreasing autophagy-mediated chemoresistance. Acquired resistance to first-line chemotherapeutics was associated with autophagy mediated by BECN1 and regulated by TXNDC17, which can be reversed by SAHA.
- Open Access
- 31 January 2024
- Published by Wiley
Psychological programs to improve the life quality and psychosocial behavior of pediatric cancer patients
Background: Emerging evidence exhibited the importance of life quality of children with pediatric cancers and their parents. The child patients generally have poor life quality and pyschological status under the intensive comprehensive therapies. Procedure: The cultural and psychological program named Ward School Program (WSP) may ease the psychological stress for the child patients. The purpose of this study is to systemically evaluate the impact of the WSP on the quality of life and psychological behavior of children with pediatric cancers. We evaluated the life quality and negative emotions of the children and their parents individually. Results: 46 child patients and their parents have accepted the invitation. compared to the occasional participation group (OP), the WSP has significantly improved the life quality satisfaction, enhanced self-conception, and promoted learning ability and attitude of the In-depth participation group (IDP), while their parents have different opinions. The parents believe that the WSP could significantly improve children’s personality problems and relieve children’s anxiety, but it has not much help on their learning skills, it indicated that it is necessary to enhance communication between parents and children for better understanding of each other. Conclusion: The WSP have postive effects on the improvement of life quality and pyschosocial behaviors for the children with pediatric cancers.
- 31 January 2024
- Published by Wiley
Open AccessPsychological programs to improve the life quality and psychosocial behavior of pediatric cancer patients
Background: Emerging evidence exhibited the importance of life quality of children with pediatric cancers and their parents. The child patients generally have poor life quality and pyschological status under the intensive comprehensive therapies. Procedure: The cultural and psychological program named Ward School Program (WSP) may ease the psychological stress for the child patients. The purpose of this study is to systemically evaluate the impact of the WSP on the quality of life and psychological behavior of children with pediatric cancers. We evaluated the life quality and negative emotions of the children and their parents individually. Results: 46 child patients and their parents have accepted the invitation. compared to the occasional participation group (OP), the WSP has significantly improved the life quality satisfaction, enhanced self-conception, and promoted learning ability and attitude of the In-depth participation group (IDP), while their parents have different opinions. The parents believe that the WSP could significantly improve children’s personality problems and relieve children’s anxiety, but it has not much help on their learning skills, it indicated that it is necessary to enhance communication between parents and children for better understanding of each other. Conclusion: The WSP have postive effects on the improvement of life quality and pyschosocial behaviors for the children with pediatric cancers.
- Open Access
- 10 May 2021
- Published by Wiley
Irinotecan Plus Doxorubicin Hydrochloride Liposome for Relapsed or Refractory Wilms Tumor
Purpose: The prognosis of the relapsed or refractory Wilms tumor (R/R WT) was dismal and new salvage chemotherapy was needed. This study aimed to evaluate the efficacy of the combination of irinotecan and doxorubicin hydrochloride liposome regimen (AI) for R/R WT. Methods: The present study enrolled the R/R WT who were treated with AI regimen at Sun Yat-Sen University Cancer Center from July 2018 to September 2020. The response was defined as the best observed response after the last two cycle and toxicity was evaluated. Result: Total of 16 patients with median age of 4.2 years (0.5 to 11 years) were enrolled, including 14 patients with relapsed disease and 2 patients with refractory disease. These patients received 1 to 8 courses (median 3 courses).14 patients were assessable for response: 2 complete response (CR), 5 partial response (PR), 2 stable disease (SD), 5 progression disease (PD). The objective response rate was 50% (2 CR, 5 PR) and the disease control rate was 64% (2 CR, 5 PR, and 2 SD). The median progression-free survival was 3.5 months (range 0.5-12 months), and the median survival duration was 8 months (range 1-28 months). Sixteen patients were assessable for toxicity, with most common grade 3 or 4 adverse events were alopecia (62%), leucopenia (40%), abdominal pain (38%), etc. No fatal adverse events have been observed. Conclusion: The AI regimen has positive efficacy with tolerated toxicity, it may provide an alternative option for the treatment of R/R WT.
- 10 May 2021
- Published by Wiley
Open AccessIrinotecan Plus Doxorubicin Hydrochloride Liposome for Relapsed or Refractory Wilms Tumor
Purpose: The prognosis of the relapsed or refractory Wilms tumor (R/R WT) was dismal and new salvage chemotherapy was needed. This study aimed to evaluate the efficacy of the combination of irinotecan and doxorubicin hydrochloride liposome regimen (AI) for R/R WT. Methods: The present study enrolled the R/R WT who were treated with AI regimen at Sun Yat-Sen University Cancer Center from July 2018 to September 2020. The response was defined as the best observed response after the last two cycle and toxicity was evaluated. Result: Total of 16 patients with median age of 4.2 years (0.5 to 11 years) were enrolled, including 14 patients with relapsed disease and 2 patients with refractory disease. These patients received 1 to 8 courses (median 3 courses).14 patients were assessable for response: 2 complete response (CR), 5 partial response (PR), 2 stable disease (SD), 5 progression disease (PD). The objective response rate was 50% (2 CR, 5 PR) and the disease control rate was 64% (2 CR, 5 PR, and 2 SD). The median progression-free survival was 3.5 months (range 0.5-12 months), and the median survival duration was 8 months (range 1-28 months). Sixteen patients were assessable for toxicity, with most common grade 3 or 4 adverse events were alopecia (62%), leucopenia (40%), abdominal pain (38%), etc. No fatal adverse events have been observed. Conclusion: The AI regimen has positive efficacy with tolerated toxicity, it may provide an alternative option for the treatment of R/R WT.
- Open Access
- 1 March 2021
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 14, 369-377
Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
Objective: The association between UGT1A1*6/*28 polymorphisms and treatment outcomes of irinotecan in children remains unknown. This retrospective study investigated the influence of UGT1A1*6/*28 polymorphisms on irinotecan toxicity and survival of pediatric patients with relapsed/refractory solid tumors. Methods: The present study enrolled a total of 44 patients aged younger than 18 years at Sun Yat-sen University Cancer Center between 2014 and 2017. Results: There were 26 boys and 18 girls; the median age at first VIT course was six years (range: 1– 18 years). The tumor types included neuroblastoma (n = 25), rhabdomyosarcoma (n = 11), Wilm’s tumor (n = 4), medulloblastoma (n = 2), and desmoplastic small round cell tumor (n = 2). Overall, 203 courses of VIT regimens were prescribed. Neither UGT1A1*6 nor *28 polymorphisms were associated with the incidence rates of severe (grade III–IV) irinotecan-related toxicities, but tended to reduce the patient overall survival (UGT1A1*6, P = 0.146; UGT1A1*28, P = 0.195). Moreover, patients with mutant UGT1A1*6 genotypes were more likely to develop grade I–IV irinotecan-related diarrhea (P = 0.043) and anemia (P = 0.002). Overall, the UGT1A1*28 polymorphism may play a protective role against irinotecan-related diarrhea and abdominal pain. Conclusion: In relapsed/refractory pediatric solid tumors, the UGT1A1*6 polymorphism was a risk factor of irinotecan-related diarrhea and anemia. The UGT1A1*28 polymorphism may serve a protective role in irinotecan-related abdominal pain and diarrhea. Both mutations had a tendency to be risk factors for survival. Nevertheless, prospective studies are required to verify such conclusions.
- 1 March 2021
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 14, 369-377
Open AccessInfluence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
Objective: The association between UGT1A1*6/*28 polymorphisms and treatment outcomes of irinotecan in children remains unknown. This retrospective study investigated the influence of UGT1A1*6/*28 polymorphisms on irinotecan toxicity and survival of pediatric patients with relapsed/refractory solid tumors. Methods: The present study enrolled a total of 44 patients aged younger than 18 years at Sun Yat-sen University Cancer Center between 2014 and 2017. Results: There were 26 boys and 18 girls; the median age at first VIT course was six years (range: 1– 18 years). The tumor types included neuroblastoma (n = 25), rhabdomyosarcoma (n = 11), Wilm’s tumor (n = 4), medulloblastoma (n = 2), and desmoplastic small round cell tumor (n = 2). Overall, 203 courses of VIT regimens were prescribed. Neither UGT1A1*6 nor *28 polymorphisms were associated with the incidence rates of severe (grade III–IV) irinotecan-related toxicities, but tended to reduce the patient overall survival (UGT1A1*6, P = 0.146; UGT1A1*28, P = 0.195). Moreover, patients with mutant UGT1A1*6 genotypes were more likely to develop grade I–IV irinotecan-related diarrhea (P = 0.043) and anemia (P = 0.002). Overall, the UGT1A1*28 polymorphism may play a protective role against irinotecan-related diarrhea and abdominal pain. Conclusion: In relapsed/refractory pediatric solid tumors, the UGT1A1*6 polymorphism was a risk factor of irinotecan-related diarrhea and anemia. The UGT1A1*28 polymorphism may serve a protective role in irinotecan-related abdominal pain and diarrhea. Both mutations had a tendency to be risk factors for survival. Nevertheless, prospective studies are required to verify such conclusions.
- Open Access
- 23 January 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (5) , e28901
Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T‐cell lymphoma in children and adolescents
Purpose: As extranodal natural killer/T‐cell lymphoma (ENKTL) occurs rarely in children and adolescents, standardized therapy is yet to be determined. This study aimed to describe the clinical features and determine the optimal chemotherapy regimen for childhood ENKTL.Methods: The treatment outcomes of radiotherapy combined with asparaginase‐based (P‐GEMOX or P‐GMED) or asparaginase‐absent chemotherapy regimens (CHOP, EPOCH, or NHL‐BFM‐90/95) in patients aged ≤18 years with newly diagnosed ENKTL from December 2006 to December 2018 were compared.Results: Among the 34 patients included in the study, 21 had stage I/II disease. The overall response rates of chemotherapy with or without asparaginase were 85.0% and 78.6%, respectively. With a median follow‐up of 54 months, the 5‐year event‐free survival (EFS) rates of patients with stage I/II and III/IV disease were 66.2 ± 11.3% and 26.0 ± 12.8%, respectively (P = .027). In stage III/IV patients treated with asparaginase‐based or asparaginase‐absent regimens, the 5‐year EFS rates were 40.0 ± 17.4% and 0%, respectively (P = .236). The 5‐year EFS rates of stage III/IV patients who received or did not receive hematopoietic stem cell transplant were 66.7 ± 27.2% and 11.1 ± 10.5%, respectively (P = .054). In addition, chemotherapy‐associated side effects were significantly less in patients treated with asparaginase‐based regimens as compared to asparaginase‐absent regimens in this cohort.Conclusion: P‐GEMOX and P‐GMED regimens are effective and safe for treating childhood ENKTL.
- 23 January 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (5) , e28901
Open AccessComparison of chemotherapy with or without asparaginase for extranodal nasal NK/T‐cell lymphoma in children and adolescents
Purpose: As extranodal natural killer/T‐cell lymphoma (ENKTL) occurs rarely in children and adolescents, standardized therapy is yet to be determined. This study aimed to describe the clinical features and determine the optimal chemotherapy regimen for childhood ENKTL.Methods: The treatment outcomes of radiotherapy combined with asparaginase‐based (P‐GEMOX or P‐GMED) or asparaginase‐absent chemotherapy regimens (CHOP, EPOCH, or NHL‐BFM‐90/95) in patients aged ≤18 years with newly diagnosed ENKTL from December 2006 to December 2018 were compared.Results: Among the 34 patients included in the study, 21 had stage I/II disease. The overall response rates of chemotherapy with or without asparaginase were 85.0% and 78.6%, respectively. With a median follow‐up of 54 months, the 5‐year event‐free survival (EFS) rates of patients with stage I/II and III/IV disease were 66.2 ± 11.3% and 26.0 ± 12.8%, respectively (P = .027). In stage III/IV patients treated with asparaginase‐based or asparaginase‐absent regimens, the 5‐year EFS rates were 40.0 ± 17.4% and 0%, respectively (P = .236). The 5‐year EFS rates of stage III/IV patients who received or did not receive hematopoietic stem cell transplant were 66.7 ± 27.2% and 11.1 ± 10.5%, respectively (P = .054). In addition, chemotherapy‐associated side effects were significantly less in patients treated with asparaginase‐based regimens as compared to asparaginase‐absent regimens in this cohort.Conclusion: P‐GEMOX and P‐GMED regimens are effective and safe for treating childhood ENKTL.